U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07532252) titled 'Daridorexant for Alcohol Use Disorder' on April 07.
Brief Summary: This study will test whether the dual orexin receptor antagonist (DORA) daridorexant reduces alcohol craving and use and improves total sleep time among patients with co-occurring alcohol use disorder and sleep disturbance. The study will assess the role of the orexin system in modulating alcohol craving and use in a real-world treatment setting.
Study Start Date: Jan. 01, 2027
Study Type: INTERVENTIONAL
Condition:
Daridorexant
Placebo - Control
Intervention:
DRUG: Daridorexant 50 mg
Daridorexant 50 mg (Orally administered)
OTHER: Placebo
Placebo (Oral)
Re...